News | September 02, 2010

SynCardia May Be for Sale in Next 12-24 Months

September 2, 2010 – Artificial heart maker SynCardia Systems said it plans to put the company up for sale some time in the next two years.

The maker of the Total Artificial Heart is considering a series E financing round before it evaluates an exit in the next 12 to 24 months, said CEO Rodger Ford. The company has raised $42.7 million in four rounds of funding to date and may seek an additional $2 to $5 million, said Ford.

SynCardia’s temporary Total Artificial Heart was approved by the FDA in 2004 as a bridge to transplant for transplant-eligible patients dying from end-stage biventricular failure. It is also cleared for use in Europe and Canada.

The company hopes to start a study in 2011 for a destination therapy product, which involves different materials than the current device.

The company plans to ramp up sales of its product and could evaluate an exit in the next 12 to 24 months. Ford said an ideal buyer would be a medical device player, such as Medtronic, Boston Scientific, St. Jude or Abbott. Medtronic and Boston Scientific are considered logical buyers because they may want to acquire cardiac pump devices like SynCardia’s to incorporate with their current offerings of stents and pacemakers.

However, SynCardia may receive greater interest from smaller companies that want to roll up the end-stage heart failure market, said Duane Nash, a senior analyst at Wedbush. He said ventricular assist device (VAD) makers Abiomed or Thoratec may have an interest, since they are already established mechanical circulatory support product vendors. Larger cardiovascular device companies may not consider SynCardia’s market large enough to go after.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For more information:

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init